Quantcast

Latest Attention-deficit hyperactivity disorder management Stories

2009-09-10 07:00:00

WALTHAM, Mass., Sept. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in the U.S., out of six million cases of major depressive disorder with comorbid panic attack, three million are untreated. Comorbid mental disorders are influential factors impacting the diagnosis and treatment of mental disorders. With this type of information drug developers can expand their markets by showing...

2009-09-09 08:59:18

Low levels of dopamine markers may underlie symptoms; implications for treatment A brain-imaging study conducted at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory provides the first definitive evidence that patients suffering from attention deficit hyperactivity disorder (ADHD) have lower-than-normal levels of certain proteins essential for experiencing reward and motivation. "These deficits in the brain's reward system may help explain clinical symptoms of ADHD,...

2009-09-09 07:00:00

TITUSVILLE, N.J., Sept. 9 /PRNewswire/ -- Attention Deficit Hyperactivity Disorder (ADHD) is estimated to impact up to 20 percent of children(1) and 4 percent of adults in the U.S.(2) Recent studies suggest ADHD is underdiagnosed: researchers estimate up to 20 percent of U.S. school-aged children meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, but only 7.8 percent report receiving an ADHD diagnosis.(3) Meanwhile, it is estimated that just 15 percent of...

2009-09-03 07:00:00

PHILADELPHIA, September 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic...

2009-08-21 15:04:29

Parents should be aware of certain behavioral symptoms in the classroom that might indicate their child should be screened for attention deficit disorder and attention deficit hyperactivity disorder, an expert at Baylor College of Medicine (www.bcm.edu) said.ADHD or ADD is present in about 5 percent of students from as young as six to adulthood, said Dr. Ayesha Mian, assistant professor of psychiatry and behavioral sciences at BCM. "Children with moderate to severe ADHD or ADD who are not on...

2009-08-17 13:43:33

Language is a central element of social life. It is not only a prerequisite for personal relationships, but also for employment prospects. If a child's language development is impaired, this can have far-reaching negative consequences. Thus, it would be beneficial if those children who would benefit from targeted help could be identified at a very early stage.However, the Institute for Quality and Efficiency in Health Care (IQWiG) could not find any proof of benefit from language screening...

2009-08-17 08:00:00

PHILADELPHIA, Aug. 17 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced two initiatives reinforcing their commitment to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral disorder that affects an estimated 10 million adults across the country.* The first initiative, "RoADHD Trip," a multi-city self screening tour, will visit eight cities across the country in an...

2009-07-28 01:00:00

PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date. The FDA did not identify safety concerns regarding INTUNIV in the...

2009-07-22 17:15:00

Vyvanse first oral ADHD stimulant with published data demonstrating significant ADHD symptom improvement from 1.5 hours up to 13 hours after administration in childrenShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of...

2009-07-22 08:00:00

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse(R)( )(lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related